Veterinary Infectious Disease Diagnostics Market Size, Share and Growth Analysis 2026 to 2035

What is Veterinary Infectious Disease Diagnostics Market Size?

Veterinary Infectious Disease Diagnostics Market Size is valued at USD 2.70 billion in 2025 and is predicted to reach USD 6.68 billion by the year 2035 at an 9.9% CAGR during the forecast period for 2026 to 2035.

Veterinary Infectious Disease Diagnostics Market Size, Share & Trends Analysis Report By Technology (Immunodiagnostics, Molecular diagnostic, Other technology), By Animal Type, By End-User, By Region, And Segment Forecasts, 2026 to 2035 

Key Industry Insights & Findings from the Report:

• The veterinary infectious disease diagnostics market is poised to capitalize on significant potential presented by growing demand from developing nations and the increasing number of vegans.
• Rising spending on animal health care and the number of pets owned are the main forces propelling the Veterinary Infectious Disease Diagnostics Market worldwide.
• North America dominated the market and accounted for a revenue share of global revenue in 2023.
• The shortage of veterinary professionals in developing nations poses the greatest threat to the forecasted expansion of the market.

Tests that assist in determining and identifying various animal illnesses are known as veterinary infectious disease diagnostics. These treatments are carried out using different techniques using tissue, excrement, and patient blood samples. Some of the factors that have led to the growth of this business include the prevalence of zoonotic diseases, the price of animal health, the number of veterinarians, the development of point-of-care diagnostics, and the level of discretionary money in emerging nations.

Veterinary infectious illnesses are the major sickness category in terms of market size. Animal diagnosis has a positive outlook, which promotes an increase in the species' population. The increasing prevalence of companion animals in households and farms will result in favourable market growth for the forecast period. Expanding research collaborations, growing research facilities, and growing direct and indirect research investments will increase the demand for the product.

The demand for pet insurance is rising, there is an increase in the number of companion animals, and there is an increase in the number of modern diagnostic tools for animals; as more companion animals contract various infectious diseases, the veterinary infectious disease diagnostics market is expanding. The development of the veterinary infectious disease diagnostics industry is, however, constrained by a need for more knowledge regarding using these instruments in less developed nations. The veterinary contagious disease diagnostics market will expand during the forecast mentioned above due to rising applications from emerging economies and increasing vegan trends, which will also present enormous opportunities.

Competitive Landscape

Some major key players in the Global Veterinary Infectious Disease Diagnostics Market:

• IDEXX Laboratories, Inc. (US),
• ZOetis, Inc. (US),
• Thermo Fisher Scientific, Inc. (US),
• Virbac(France),
• bioMerieux SA (France)
• Heska Corporation (US),
• Idvet (France),
• NEOGEN Corporation (US),
• QIAGEN N.V. (a part of INDICAL Biosicence) (Europe),
• Randoxz Laboratories Ltd. (UK),
• Agrolabo S.pA. (Italy),
• Bio-Rad Laboratories (US),
• Bionote, Inc.(South Korea),
• Biogal Galed Labs (Isreal),
• BioChek (Netherlands),(UK)
• Biopanda Regrants(UK),
• URIT Medical Electric Co.Ltd. (China),
• MEGACOR Diagnostik GmbH (Germany),
• Fassisi GmbH (Germany),
• Alvedia (France),
• SKYER, Inc. (South Korea),
• Shenzhen Bioeasy Biotechnology Co., Ltd. (China) ,
• Precision Biosensor (US).

Market Segmentation:

The veterinary infectious disease diagnostics market is divided into technology, animal type,  and end-use. Based on technology, the veterinary infectious disease diagnostics market is segmented into immunodiagnostics (lateral flow assays, elisa tests, other immunodiagnostics products), molecular diagnostic (polymerase chain reaction (PCR) tests, microarrays, other molecular diagnostic products) and other technologies. Based on animal type, the veterinary infectious disease diagnostics market is segmented into companion animals (cats, dogs, horses, other companion animals), companion animals by infection type (viral infections, bacterial infections, parasitic infections, other infections), food-producing animals (cattle, pigs, poultry, other food-producing animals) and food-producing animals, by infection type (viral infections, bacterial infections, parasitic infections, other infections). The veterinary infectious disease diagnostics market is divided into reference laboratories, veterinary hospitals and clinics, point-of-care/in-house testing, research institutes and universities.

Based on product, the immunoassays segment is a major contributor to the veterinary infectious disease diagnostics market.

The market's leading segment is immunoassays. The growing use of immunoassays in the diagnosis of infectious diseases, the creation of novel tests, the rising trend of automation, the rise in public awareness of fitness and health, and the decreased complications caused by the instruments are the fundamental causes of this market's domination. However, antibody and antigen detection by immunoassays is the primary method by which the infection is established in some infectious disorders, such as Lyme disease, cryptococcal meningitis, and syphilis. Immunoassays are increasingly available for point-of-care testing due to their simplicity, quick turnaround time, and generally excellent specificity. These elements will cause the market to see expansion throughout the anticipated timeframe.

The reference laboratories segment witnessed growth at a rapid rate.

Reference laboratories grabbed the highest revenue share, and it is anticipated that they will continue to hold that position during the anticipated time. The enormous number of samples from small and large animal practices sent to reference laboratories for analysis may cause a significant share of this end-user category. The healthcare sector's increased production of medical samples and developments in some medical specialties, including hematology and serology, is anticipated to be the primary growth drivers for the clinical reference laboratory services market. Another significant growth driver for the clinical reference laboratory services has been the research and advanced studies carried out in cytogenetics, tumors, and human genomes, all of which are fundamental components of the broader microbiology field.

The North American veterinary infectious disease diagnostics market holds a significant regional revenue share.

The North American veterinary infectious disease diagnostics market is expected to register the highest market share. The cost increase demonstrates owners' desire to take their pets for diagnostic tests. These elements will cause the market to expand significantly in the future years. Due to the rapid adoption of pets, rising spending on animal health, the availability of advanced diagnostic technologies and favorable pet insurance coverage, the prevalence of major market players, and the rise in zoonotic diseases, the U.S. currently dominates the global market for veterinary infectious disease diagnostics. This trend is expected to continue during the forecast period. Besides, Asia pacific region is estimated to hold a significant market share. The region's market is expanding due to increasing zoonotic disease occurrences and rising demand for diagnostics for infectious diseases. Owners' desire to take their dogs for diagnostic tests is evident in the cost increase. The market will grow significantly in the coming years due to these factors. Additionally, the expansion of the regional market as a whole is being greatly aided by an increase in R&D activities and a good healthcare infrastructure.

Recent Developments:

• In January 2026, IDEXX Laboratories, Inc. (NASDAQ: IDXX), a global leader in pet healthcare innovation, unveiled the IDEXX in Vue DxTM Cellular Analyzer. This revolutionary device is the first of its kind and can diagnose the most common cytologic abnormalities found in blood and ear samples.

• In January 2026, Neogen Corporation introduced the SureKill Gel Bait Pro Applicator, the newest SureKill line of pest control solutions member.

• In June 2025, Chembio Diagnostics, Inc., a front-runner in infectious disease point-of-care diagnostics, announced that it had received a Clinical Laboratory Improvement Amendments (CLIA) waiver for the DPP HIV-Syphilis System from the U.S. Food and Drug Administration (FDA).

Global Veterinary Infectious Disease Diagnostics Market Report Scope